Benefits Overview Enrollment & Participation Engagement & Persistence Clinical Outcomes Clinical Pathway Medical Utilization Program Performance Member Experience Engagement & Outcomes

AT&T · Employer portal

Engagement & Clinical Outcomes

Participation, engagement, barriers, and aggregate health trends.

Privacy: no group under 11 shownSample data

Weight loss ≥5%

61%

achieved meaningful loss

Measured

6-month persistence

79%

remain on treatment

Observed

Meaningful actions / week

2.8

per active member

Observed

Timely follow-up

80%

258 of 323 cases

Observed

Enrollment to outcomes funnel

Privacy: no group under 11 shown

Eligible

30,000Observed

Signed up

2,000Observed

Baseline completed

1,766Observed

Therapy started

1,678Observed

Active at 90 days

1,524Observed

Active at 6 months

1,326Observed

Active at 12 months

1,158Observed

Measurable improvement

1,009Measured

Program persistence

Cohort

PayRX cohort retention vs. an illustrative industry benchmark. At 12 months, 1,158 members remain active.

Engagement frequency

1,326 active members

Daily check-ins955 (72%)

Weekly check-ins239 (18%)

Monthly or less133 (10%)

Avg check-ins / week

3.2

Observed

Message response rate

84%

Observed

Refill adherence

91%

Observed

Barriers & support

Discontinuation reasons

Side effects

20 (31.3%)

Cost / coverage

14 (21.9%)

Refill difficulties

10 (15.6%)

Clinical decision

8 (12.5%)

Other / unknown

12 (18.8%)

Total discontinued64 (100%)

Among 64 members who discontinued within 12 months. Each member has one primary reason.

Timely follow-up

80%

258 of 323 cases requiring follow-up received a same-day response.

Measured

61%

Weight loss ≥5%

n = 1,285

45% benchmark

Measured

-9.9%

Avg weight change

from baseline

-5.2% benchmark

Measured

8 mmHg

Systolic BP drop

average reduction

4 mmHg benchmark

Measured

0.5%

HbA1c reduction

average reduction

0.3% benchmark

A1C Impact & Value

— what happens when A1C drops, and what it’s worth

Average HbA1c · Last 12 months

8.2%

Baseline

7.7%

After 12 months

−0.5 pp

reduction

Clinical target: <7.0%0.7 pp above target

Diabetic-range members

874

of 1,285 with follow-up

A1C improved

629

72% of diabetics

Clinical risk reduction

UKPDS-based

Each 1 percentage-point A1C drop reduces complication risk. At −0.5 pp:

Microvascular complications (kidney, eye, nerve)−18.5%

Per 1 pp drop: −37%

Diabetes-related mortality−10.5%

Per 1 pp drop: −21%

Heart attack−7.0%

Per 1 pp drop: −14%

Stroke−6.0%

Per 1 pp drop: −12%

A1C distribution shift

n = 874

Members moving from uncontrolled toward controlled range:

Controlled (<7.0%)15% → 38%

Uncontrolled (7.0–8.9%)55% → 47%

Very uncontrolled (≥9.0%)30% → 15%

Before After

Financial value of A1C reduction

Modeled

Annual cost avoidance per improved member

Hospitalizations avoided

$1,500

ER visits avoided

$350

Medication optimization

$550

Absenteeism (2 fewer days)

$620

Total per member / year$3,020

Total value · 12 months

$1.90M

Medical cost avoidance$1.51M

Productivity recovery$390K

Based on 629 members with A1C improvement. Modeled, not realized — see Financial Impact for validation status.

Weight loss distribution

n = 1,285

≥10% weight loss308 (24%)

5–10% weight loss475 (37%)

<5% weight loss360 (28%)

No change / gained141 (11%)

BMI change & data completeness

Average BMI

33.8 → 30.5

among 643 members with paired measurements

Follow-up measurement coverage

Weight

638/83976%

Blood pressure

579/83969%

HbA1c

403/83948%

Lipids

445/83953%

All outcomes are measured from paired baseline and follow-up values. Benchmarks are illustrative, not validated external data.

Employee Privacy Protected by Design

Employer reporting is designed to present aggregate workforce and health-program insights without exposing individual clinical records. Small-group reporting restrictions help reduce the risk of employee identification.

Sample dataPrivacy-restricted reporting

Aggregated information is not described as HIPAA-de-identified unless applicable de-identification requirements have been satisfied and verified.